Randomized phase 2 trial of intravenous oncolytic virus JX-594 …
网页2022年10月21日 · JX-954 also infects tumor-associated endothelial cells in a dose-dependent manner and induces vascular disruption. JX-594 has demonstrated a favorable safety profile and activity in preclinical and early clinical studies, both after intra-tumoral (IT), single and repeated intravenous (IV) injections at dose up to 3 × 10 9 pfu/dose [ 3 , 4 ].
Abstract - American Association for Cancer Research
网页2022年6月15日 · JX-594 (Pexavec, SillaJen) is an attenuated (TKdeactivated ) oncolytic vaccinia VV, engineered to express GM-CSF and to selectively target tumor over non-tumor tissues. It is currently being investigated as a novel therapeutic option in patients with advanced Renal Cell Carcinoma (RCC, NCT03294083).
Liver cancer survival time tripled by virus - ScienceDirect
网页2013年2月16日 · The virus, code-named JX-954, targets two genes involved in cancer cell growth and blood supply, which show increased activity in tumours. The virus reduces this activity, killing cancer cells. “Some tumours disappeared completely, and most showed partial destruction on MRI scans,” says David Kirn of Jennerex.
网页JX‐594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemo‐ therapy has shown preclinical synergy with oncolytic viruses.
Oncolytic Immunotherapy: Conceptual Evolution, Current …
网页2017年5月15日 · To date, the most encouraging results have been obtained in a trial using Pexa-Vec (JX-954) to treat patients with liver cancer , where coordinate viral replication and GM-CSF expression in tumors was observed, with therapy-induced antitumor immunity also being detected. In this trial, the duration of patient survival was directly related to ...
The biology of Hepatocellular carcinoma: implications for genomic …
网页2017年8月30日 · In a Phase II dose-finding clinical trial, JX-594 was administered at two doses (low-dose (10 8 PFU) and high-dose (10 9 PFU) of JX-594). The study was terminated early as patients receiving higher doses of JX-954 showed a significant longer overall median survival (14.1 months in the high-dose group versus 6.7 months in the low-dose group) [ 77 ].
Role of regorafenib as second-line therapy and landscape of ...
网页2016年9月21日 · JX-594 is aimed to induce virus replication-dependent lysis of tumor cells as well as to induce tumor-specific immunity. In a Phase II clinical trial, JX-594 was administered in two doses: low-dose (10 8 PFU) and high-dose (10 9 PFU) JX-594 in patients with advanced HCC.
Advances and potential pitfalls of oncolytic viruses expressing ...
网页2020年6月25日 · In addition, recent advances in viral therapy, of which the most promising are perhaps viruses such as DNX-2401, PVS-RIPO, and Toca 511, have shown complete durable responses in ~20% of GBM ...
Cancer-Fighting Engineered Virus Makes Medical History
网页Scientists, including teams from the Ottawa Hospital Research Institute, the University of Ottawa, and the private biotechnology company, Jennerex, say the engineered virus, called JX-954, replicated itself in the patient's tumors, but left normal, healthy tissues unaffected in seven of the eight patients in the two highest-dose groups.
Abstract 3293: In vitro cellular and molecular effects of oncolytic ...
网页2022年6月15日 · The present study was undertaken to investigate the effects of JX-954 in a panel of clear and non-clear cell RCC cell lines and characterize the potential mechanisms of JX-594 oncolysis in...
- 某些结果已被删除
跳至内容